B. Carreno
Genetics · 2000–2020
A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Genetics — 16 citations into it
Whom B. Carreno trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts B. Carreno overall
Papers from B. Carreno's perspective
Ordered by how strongly the researchers B. Carreno trusts endorse each paper. Same corpus, a different order for every researcher.
- Integrative Genomics Viewer (Nature Biotechnology)
- Prediction of MHC class I binding peptides using profile motifs. (Human Immunology)
- The Sequence Alignment/Map format and SAMtools (Bioinform.)
- NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence
- The immune epitope database (IEDB) 3.0 (Nucleic Acids Res.)
- NetMHCpan, a method for MHC class I binding prediction beyond humans
- SomaticSniper: identification of somatic point mutations in whole genome sequencing data (Bioinform.)
- Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs (Bioinform.)
- A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data (Bioinform.)
- Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor
Their papers
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells (2015) — 1,091 citations
- pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens (2016) — 392 citations
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013) — 1,129 citations
- CRISPR-engineered T cells in patients with refractory cancer (2020) — 1,260 citations
- A Vaccine for Cancer? (2016)
- PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 (2002) — 721 citations
- The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. (2002) — 981 citations
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation (2001) — 2,945 citations
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (2000) — 5,135 citations